Literature DB >> 20618768

Intradermal delivery of recombinant vaccinia virus vector DIs induces gut-mucosal immunity.

N Yoshino1, M Kanekiyo, Y Hagiwara, T Okamura, K Someya, K Matsuo, Y Ami, S Sato, N Yamamoto, M Honda.   

Abstract

Antigen-specific mucosal immunity is generally induced by the stimulation of inductive mucosal sites. In this study, we found that the replication-deficient vaccinia virus vector, DIs, generates antigen-specific mucosal immunity and systemic responses. Following intradermal injection of recombinant DIs expressing simian immunodeficiency virus gag (rDIsSIVgag), we observed increased levels of SIV p27-specific IgA and IgG antibodies in faecal extracts and plasma samples, and antibody-forming cells in the intestinal mucosa and spleen of C57BL/6 mice. Antibodies against p27 were not detected in nasal washes, saliva, and vaginal washes. The enhanced mucosal and systemic immunity persisted for 1 year of observation. Induction of Gag-specific IFN-gamma spot-forming CD8(+) T cells in the spleen, small intestinal intraepithelial lymphocytes, and submandibular lymph nodes was observed in the intradermally injected mice. Heat-inactivated rDIsSIVgag rarely induced antigen-specific humoral and T-helper immunity. Moreover, rDIsSIVgag was detected in MHC class II IA antigen-positive (IA(+)) cells at the injection site. Consequently, intradermal delivery of rDIs effectively induces antigen-specific humoral and cellular immunity in gut-mucosal tissues of mice. Our data suggest that intradermal injection of an rDIs vaccine may be useful against mucosally transmitted pathogens.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20618768     DOI: 10.1111/j.1365-3083.2010.02416.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  4 in total

1.  Novel vaccine regimen elicits strong airway immune responses and control of respiratory syncytial virus in nonhuman primates.

Authors:  Thomas Grunwald; Matthias Tenbusch; Reiner Schulte; Katharina Raue; Hans Wolf; Drew Hannaman; Rik L de Swart; Klaus Uberla; Christiane Stahl-Hennig
Journal:  J Virol       Date:  2014-01-22       Impact factor: 5.103

Review 2.  Differential Immune Response Following Intranasal and Intradermal Infection with Francisella tularensis: Implications for Vaccine Development.

Authors:  McKayla J Nicol; David R Williamson; David E Place; Girish S Kirimanjeswara
Journal:  Microorganisms       Date:  2021-04-30

3.  Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01.

Authors:  Jes Dietrich; Lars Vibe Andreasen; Peter Andersen; Else Marie Agger
Journal:  PLoS One       Date:  2014-06-23       Impact factor: 3.240

4.  Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized placebo-controlled trial.

Authors:  Jessica W Crothers; Elizabeth Ross Colgate; Kelly J Cowan; Dorothy M Dickson; MaryClaire Walsh; Marya Carmolli; Peter F Wright; Elizabeth B Norton; Beth D Kirkpatrick
Journal:  Vaccine       Date:  2022-03-30       Impact factor: 4.169

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.